Evidence map›Paper›PMID 32859626›Full record

ReviewCancer genomics & proteomics

microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical

Ulrich H Weidle, Ulrich Brinkmann, Simon Auslaender

Open access · diamondAbstract readReview
In one paragraph

Review in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ulrich H WeidleLarge Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany weidle49@t-online.de simon.auslaender@roche.com.
Ulrich BrinkmannLarge Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Simon AuslaenderLarge Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany weidle49@t-online.de simon.auslaender@roche.com.
Roche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high death toll of colorectal cancer patients is due to metastatic disease which is difficult to treat. The liver is the preferred site of metastasis, followed by the lungs and peritoneum. In order to identify new targets and new modalities of intervention we surveyed the literature for microRNAs (miRs) which modulate metastasis of colorectal cancer in preclinical in vivo models. We identified 12 up-regulated and 19 down-regulated miRs corresponding to the latter criterium. The vast majority (n=16) of identified miRs are involved in modulation of epithelial-mesenchymal transition (EMT). Other categories of metastasis-related miRs exhibit tumor- and metastasis-suppressing functions, modulation of signaling pathways, transmembrane receptors and a class of miRs, which interfere with targets which do not fit into these categories. Finally, we discuss the principles of miR inhibition and reconstitution of function, prospective clinical evaluation of with miR-related agents in the context of clinical evaluation in metastasis relevant settings.

Indexed as

AnimalsAntineoplastic AgentsBiomarkers, TumorCell Line, TumorColorectal NeoplasmsDisease Models, AnimalEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansLiver NeoplasmsLung NeoplasmsMicroRNAsPeritoneal NeoplasmsSignal TransductionXenograft Model Antitumor AssaysAntineoplastic AgentsBiomarkers, TumorMicroRNAsEpithelial-mesenchymal transition (EMT)invasion and migrationin vivo metastasis-related modelsliver metastasismicroRNA (miR)miR-related therapeutic agentsoncogenic signaling pathwaysreviewTGFβ signalingtumor- and -metastasis suppressors

Identifiers

PMID32859626
PMCPMC7472456
OpenAlexW3082840491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.